How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Central Lab Market
- By Service Type: Clinical Chemistry Testing, Hematology Testing, Molecular Diagnostics, Immunology Testing, Microbiology Testing, Pathology Testing
- By End User: Pharmaceutical Companies, Biotechnology Firms, Hospitals and Clinics, Academic and Research Institutes, Contract Research Organizations (CROs)
- By Sample Type: Blood Samples, Urine Samples, Tissue Samples, Saliva Samples, Cerebrospinal Fluid Samples
- By Technology Platform: High-Throughput Screening, Next-Generation Sequencing (NGS), Mass Spectrometry, Polymerase Chain Reaction (PCR), Flow Cytometry
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Clinical Chemistry Testing leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 286 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.171 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Central Lab Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →LabCorp (Laboratory Corporation of America Holdings)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Quest Diagnostics Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Eurofins Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →PPD
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inc. (Pharmaceutical Product Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Covance Inc. (a part of LabCorp)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →PRA Health Sciences (now part of ICON plc)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →SGS SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →WuXi AppTec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →BioAgilytix Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Medpace Holdings Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Synexus Clinical Research
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Q2 Solutions (a joint venture between IQVIA and Quest Diagnostics)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Sonic Healthcare Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Clinical Chemistry Testing25.5
- Hematology Testing17.3
- Molecular Diagnostics12.9
- Immunology Testing16.0
- Microbiology Testing7.3
- Pathology Testing21.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- LabCorp (Laboratory Corporation of America Holdings)21.4
- Quest Diagnostics Incorporated15.3
- Eurofins Scientific7.3
- ICON plc10.9
- PPD10.5
- Inc. (Pharmaceutical Product Development)6.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.6
- Europe21.3
- Asia Pacific21.3
- Latin America13.2
- Middle East and Africa9.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| LabCorp (Laboratory Corporation of America Holdings) | 86 | 99 | 80 | 74 | 93 | 81 | 86 |
| Quest Diagnostics Incorporated | 71 | 74 | 80 | 68 | 68 | 89 | 75 |
| Eurofins Scientific | 66 | 85 | 71 | 85 | 65 | 85 | 76 |
| ICON plc | 59 | 72 | 61 | 68 | 58 | 78 | 66 |
| PPD | 52 | 74 | 52 | 62 | 64 | 65 | 62 |
| Inc. (Pharmaceutical Product Development) | 61 | 53 | 53 | 53 | 51 | 62 | 56 |
| Charles River Laboratories International Inc. | 54 | 57 | 54 | 50 | 56 | 47 | 53 |
| Covance Inc. (a part of LabCorp) | 50 | 45 | 58 | 58 | 54 | 54 | 53 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- LabCorp (Laboratory Corporation of America Holdings)
- Quest Diagnostics Incorporated
- Eurofins Scientific
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| LabCorp (Laboratory Corporation of America Holdings) | ◐ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Quest Diagnostics Incorporated | − | − | ✓ | ◐ | ◐ | ◐ |
| Eurofins Scientific | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| ICON plc | − | ✓ | − | ✓ | − | ◐ |
| PPD | − | ◐ | − | ◐ | ◐ | ◐ |
| Inc. (Pharmaceutical Product Development) | ◐ | ◐ | − | ◐ | ◐ | − |
| Charles River Laboratories International Inc. | − | − | − | − | ◐ | ◐ |
| Covance Inc. (a part of LabCorp) | − | ◐ | ◐ | ◐ | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche3
Specialists in a single segment or region.
Go-to-market strategy
Land Service Type in North America, then scale across Central Lab Market — a $470M beachhead inside a $7.45B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Clinical Chemistry Testing
Best fit — highest urgency & budget in Service Type.
Hematology Testing
Strong fit — clear ROI and a fast path to value.
Molecular Diagnostics
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sample Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Central Lab Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Central Lab Market is a durable-growth opportunity — $8.07B by 2033, compounding at 7.8%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.8% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Central Lab Market — a $1.53B market by 2033. Plan: grow share from 8.6% to 14.8%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.6% | 14.8% | At risk |
| Revenue | $142M | $227M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 28.6% | 41.1% | Ahead |
| Customer retention | 89.7% | 92.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $32M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Sales deck · value proposition
Win the Central Lab Market conversation — a $4.00B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Central Lab Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Central Lab Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Heart Health Products Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportCentralized Patient Monitoring System Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCentral Infusion Management System Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportCentral Fill as a Service Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportCentral Fetal Monitoring Station Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportCentral Anaesthetic Gas Scavenging Systems Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportCenterline IV Cannula Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportCenicriviroc Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCementless Knee System Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportCementless Hip Stem System Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCementless Femoral Stem Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportCementless Acetabular Prosthesis Market
Market size, share, segmentation and regional forecast.
$893M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy